Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

• ClinicalTrials.gov Identifier: NCT00587223
• Recruitment Status: Terminated
• First Posted: January 7, 2008
• Results First Posted: June 22, 2010
• Last Update Posted: June 29, 2010
• Sponsor: Organogenesis
• Information provided by: Organogenesis

Study Description

Brief Summary:

The purpose of this study is to evaluate the use of Apligraf for the treatment of nonhealing wounds in subjects with dystrophic or junctional epidermolysis bullosa. Apligraf will be evaluated for efficacy and safety compared to a conventional nonadherent dressing. A matched-pair design will be used to evaluate Apligraf treatment versus conventional treatment in 68 study pairs.

Condition or disease	Intervention/treatment	Phase
Epidermolysis Bullosa, Junctional; Epidermolysis Bullosa Dystrophica	Device: Apligraf; Other: Standard dressing regimen	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 1 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Prospective, Multicenter, Within Subject Controlled Study to Evaluate the Effect of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa
• Study Start Date: December 2007
• Actual Primary Completion Date: December 2008
• Actual Study Completion Date: December 2008

Arms and Interventions

Arm	Intervention/treatment
Experimental: 1; Apligraf (a living bilayered cell therapy product)	Device: Apligraf; Up to 3 applications: Day 0, Month 1, Month 2.
Active Comparator: 2; Dressing regimen comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer.	Other: Standard dressing regimen; Dressing regimen will be comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer

Outcome Measures

Primary Outcome Measures :

1. Proportion of Wounds First Achieving 100% Epithelialization of Tissue With the Absence of Drainage (i.e. Complete Wound Closure) Through Study Week 12 [ Time Frame: Through 12 weeks ]

Secondary Outcome Measures :

1. Time Until Complete Closure [ Time Frame: through 12 weeks ]
2. Rate of Complete Wound Closure Over Time [ Time Frame: through 12 weeks ]
3. Recurrence of Epidermolysis Bullosa (EB) Lesions [ Time Frame: through 12 months ]
4. Reduction of Intensity of Pain [ Time Frame: through 12 weeks ]
5. Proportion of Wounds Experiencing an Adverse Event [ Time Frame: through 12 months ]

Eligibility Criteria

• Ages Eligible for Study: 2 Years to 65 Years (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Subject is between 2 and 65 years of age.
• Subject with clinical and histological diagnosis of junctional or dystrophic EB with documented electron microscopy or immunofluorescence microscopy.
• Subject has at least two non-adjacent EB lesions, at least 4 cm apart. The two selected EB lesions must be relatively matched in terms of diagnosis, location, level of erosion and size. Lesions may be on the same limb.
• Subject with dystrophic or junctional EB lesions between 10-44 cm2 present for at least 6 weeks. For the purposes of this study, a lesion is defined as a wound resulting from a post blister erosion.
• Subject who is a female of child-bearing potential (females >10 years of age) must have a documented negative urine or serum pregnancy test. Sexually active females must be practicing a medically proven form of contraception during the course of the study period.
• Subject or legal guardian must have read, understood and signed an institutional review board (IRB) approved Informed Consent Form or Assent Form.
• Subject and/or legal guardian must be able and willing to follow study procedures and instructions.

Exclusion Criteria:

• Subject with lesions only on the soles, posterior thigh or gluteus maximus.
• Subject whose lesion has healed 20% or greater in area from post debridement (if applicable) Baseline Screen (Visit 1) to post debridement Day 0 (Visit 2) as determined by wound tracings.
• Subject with uncontrolled diabetes mellitus (glycosylated HbA1C > 10%), cancer (biopsy confirmed active malignancy), or positive HIV test.
• Subject is a child (<18 years of age) who is currently receiving or has received oral steroid therapy exceeding a total daily dose of 0.5mg/kg for more than two weeks, radiation or other immuno-suppressive therapy which would interfere with wound healing within the past four weeks.
• Subject is an adult (>18 years of age) who is currently receiving or has received chronic high dose steroid therapy exceeding a total daily dose of 20mg for more than two weeks, radiation or other immuno-suppressive therapy which would interfere with wound healing within the past four weeks.
• Subject who is currently on or has received topical steroidal therapy within 30 days before screening. Inhaled steroids are allowed.
• Subject with the presence of acute infections in the areas intended for treatment.
• Subject with a history of squamous cell carcinoma.
• Known hypersensitivity to bovine collagen or to the components of the Apligraf agarose shipping medium.
• Subject who is lactating or pregnant (hCG positive as determined by lab testing).
• Subject is a child (<18 years of age) with liver (ALT/SGPT, ALP, AST/SGOT, bilirubin, total protein, LDH) and/or renal function (BUN and creatinine) tests > 2 x upper limit of normal (ULN). Albumin < 2.0 mg/dL.
• Subject is an adult (>18 years of age) with liver (ALT/SGPT, ALP, AST/SGOT, bilirubin, total protein, LDH) and/or renal function (BUN and creatinine) tests > 2 x upper limit of normal (ULN). Albumin < 2.0 mg/dL.
• Subject enrolled in any wound or investigational device study for any disease within the past four weeks.
• Subject who has received an investigational drug or biological treatment within three months.
• Subject previously treated with Apligraf, Dermagraft or any other cell therapy at the target sites.
• Subject with a history of alcohol or substance abuse within the previous year, which could interfere with study compliance such as inability to attend scheduled study visits or compliance with home dressing changes.
• Subject who, in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol.

Contacts and Locations

Locations

United States, California

Stanford University School of Medicine

Stanford, California, United States, 94305-5168

United States, Florida

University of Miami - Miller School of Medicine

Miami, Florida, United States, 33125

United States, New York

Columbia University Medical Center

New York, New York, United States, 10032

United States, Ohio

Children's Hospital of Cincinnati

Cincinnati, Ohio, United States, 45229

United States, Texas

University of Texas

Houston, Texas, United States, 77030-1341

Sponsors and Collaborators

Organogenesis

Investigators

• Principal Investigator: Elizabeth Alvarez- Connelly, MD; University of Miami
• Study Director: Damien Bates, MD, PhD, FRACS (Plast.); Organogenesis Inc.

More Information

• Responsible Party: Katherine B. Giovino, Director of Clinical Operations, Organogenesis Inc.
• ClinicalTrials.gov Identifier: NCT00587223
• Other Study ID Numbers: 06-EB-001-AG
• First Posted: January 7, 2008
• Results First Posted: June 22, 2010
• Last Update Posted: June 29, 2010
• Last Verified: June 2010

Additional relevant MeSH terms:

Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional; Skin Abnormalities; Congenital Abnormalities; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin Diseases; Skin Diseases, Vesiculobullous; Collagen Diseases; Connective Tissue Diseases